Vivek S Radhakrishnan

Employment

• University Hospital Southampton NHS Foundation Trust Consultant in Haematology- Lymphoma, Myeloma, Early phase clinical trials & CAR-T
  2022 - Present
• Tata Medical Center Consultant & Attending Physician
  2017 - 2022
• Aster Medcity Lead Consultant
  2014 - 2016

Education

• University Hospital Southampton NHS Foundation Trust Senior Research Fellowship (RCP ST7)
  2022 - 2023
• Tata Medical Center Post-doctoral fellowship in Bone Marrow Transplantation
  2011 - 2012
• Madras Medical College DM, Doctorate of Medicine
  2007 - 2010

Projects & Funding

Projects & funding information is unavailable.

Publications (85)

• Relapsed/Refractory Hodgkin lymphoma after first-line escalated beacopdac: Adverse outcomes are overcome by use of second-line targeted therapy - an international real-world analysis
  Blood 2025 DOI: 10.1182/blood-2025-3623
  +Save
• Antibody-Based Therapies for the Treatment of Hodgkin Lymphoma in Older Patients
  Journal of Clinical Oncology 2025 DOI: 10.1200/JCO-25-01022
  +Save
• Randomised Phase II study of acalabrutinib in combination with R-CHOP treatment for diffuse large B-cell lymphoma confirms safety and unimpaired treatment delivery
  Blood 2025 DOI: 10.1182/blood-2025-5459
  +Save
• Delays to Diagnosis of Peripheral T-Cell Lymphoma and Clinical Utility of Molecular Profiling: A UK Multicentre Real-World Study
  Blood 2024 DOI: 10.1182/blood-2024-205820
  +Save
• Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
  Blood 2024 DOI: 10.1182/blood-2024-199779
  +Save
• Healthy tissue metabolism assessed by [18F]FDG PET/CT as a marker of prognosis and adverse events in advanced Hodgkin lymphoma patients
  Scientific Reports 2024 DOI: 10.1038/s41598-024-63349-5
  +Save
• Secondary Histiocytic Sarcoma in a Pre-B-Acute Lymphoblastic Leukemia
  Indian Journal of Medical and Paediatric Oncology 2024 DOI: 10.1055/s-0043-1778110
  +Save
• Chimeric Antigen Receptor T-cell based cellular therapies for cancer: An introduction and Indian perspective
  Indian Journal of Cancer 2024 DOI: 10.4103/ijc.ijc_433_21
  +Save
• Bispecific antibodies in indolent B-cell lymphomas
  Frontiers in Immunology 2024 DOI: 10.3389/fimmu.2023.1295599
  +Save
• Antibody based therapies in Hodgkin Lymphoma
  Cancer Treatment Reviews 2023 DOI: 10.1016/j.ctrv.2023.102647
  +Save